tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Immutep Gains FDA Support for Cancer Therapy Development

Story Highlights
Immutep Gains FDA Support for Cancer Therapy Development

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Immutep Ltd ( (AU:IMM) ) has shared an announcement.

Immutep Limited has received positive feedback from the FDA regarding the clinical development of its MHC Class II agonist, eftilagimod alfa, for treating head and neck squamous cell carcinoma patients with low PD-L1 expression. The FDA’s support highlights the potential of eftilagimod alfa in combination with KEYTRUDA to address unmet medical needs in this patient segment, paving the way for further clinical trials and potential accelerated approval, which could significantly impact the company’s operations and industry positioning.

The most recent analyst rating on (AU:IMM) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.

More about Immutep Ltd

Immutep Limited is a late-stage biotechnology company that develops novel immunotherapies for cancer and autoimmune diseases. The company is a pioneer in the development of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), leveraging its expertise to create innovative treatments and maximize shareholder value.

Average Trading Volume: 3,399,110

Technical Sentiment Signal: Sell

Current Market Cap: A$381.6M

Find detailed analytics on IMM stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1